CD4 and ovarian neoplasm: Regarding our results showing that the murlentamab opsonization of SKOV3-R2+ ovarian tumor cells promote the orientation of macrophages towards an M1-like profile expressing soluble mediators involved in T cell recruitment and/or activation (Figure 3), we explored its impact on the adaptive immune cells, especially CD4+, CD8+ and Tregs.